Top Markets
#1 Ontology Gas Ontology Gas +45.07%
#2 Fake World Assets Fake World Assets +22.08%
#3 Anvil Anvil +19.32%
#4 ETHGas ETHGas +19.07%
#5 Status Status +17.96%
#6 The Black Bull The Black Bull +17.02%
#7 Geodnet Geodnet +16.47%
#8 Ontology Ontology +11.87%
#9 Derive Derive +10.68%
#10 Gas Gas +9.27%
Coin of the day
Ontology Gas Ontology Gas
Innstillinger
Språk
NORSK
Valuta
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rangering i aksjer #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Aksjekurs
$9.81
Sist synkronisert: 2025-03-18
Markedsverdi
$48.68M
Endring (1 dag)
1.55%
Endring (1 år)
0.00%
Land
US
Handel AlloVir, Inc. (ALVR)

Kategori

Healthcare
Inntekter for AlloVir, Inc. (ALVR)
Inntekter i Jun 2026 TTM: 0.00
Ifølge de nyeste økonomiske rapportene til AlloVir, Inc. er selskapets nåværende inntekter (TTM) 0.00. I 2023 hadde selskapet inntekter på 0.00 lik inntektene i 2022, som var 0.00. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for AlloVir, Inc. fra 2018 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $165.00K -85.46%
2018 $1.14M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US